Johnson & Johnson (JNJ) has shown promising growth, selling shares to banks and investors, from Skandinaviska Enskilda Banken AB publ to Auto Owners Insurance Co. Seeing this as a good investment opportunity, Jim Cramer recommends jumping on the momentum. Q2 earnings for 2025 have performed well. Improving economic predictions have allowed JNJ to drop their tariff cost outlook in half. Even Precision, Lifeworks Advisors, and Madison Asset Management LLC are interacting with JNJ, recognizing the value of the stock.
Furthermore, Johnson & Johnson's work in biotech as shown by its FDA Priority Review for TAR-200 NDA for high-risk, non-invasive bladder cancer and results showing Pasritamig's potential in prostate cancer research, also strengthens the momentum for the stock. The company's innovative approach was recognized by its inclusion in Fortune's 2025 America's Most Innovative Companies list.
While there are indications of patent cliffs looming, increased involvement and new investment from Davis Rea LTD., Proficio Capital Partners, and Hendershot Investment indicates confidence in mitigating this risk.
Overall, Johnson & Johnson's recent actions sport a promising future for its growth and contributions in the biotech industry.
Johnson Johnson JNJ News Analytics from Tue, 15 Oct 2024 07:00:00 GMT to Sat, 26 Jul 2025 12:40:42 GMT - Rating 7 - Innovation 8 - Information 8 - Rumor 2
